IL10 and systemic lupus erythematosus: To explore IL-10 effects on immune cells and disease in the inflamed in vivo setting of lupus, 20–22 week old NZB/W F1 animals with detectable autoantibody titers were treated with anti-IL-10R antibodies (α-IL-10R) or isotype control at a dose of 500 μg every 3 weeks over 6 weeks.